Literature DB >> 16189089

Evaluation of LBM415 (NVP PDF-713), a novel peptide deformylase inhibitor, for treatment of experimental Mycoplasma pneumoniae pneumonia.

Monica Fonseca-Aten1, Christine M Salvatore, Asunción Mejías, Ana M Ríos, Susana Chávez-Bueno, Kathy Katz, Ana M Gómez, George H McCracken, R Doug Hardy.   

Abstract

Mycoplasma pneumoniae is a major cause of community-acquired pneumonia. We evaluated the efficacy of LBM415, a novel peptide deformylase inhibitor antimicrobial agent, for the treatment of M. pneumoniae pneumonia in a mouse model. Eight-week-old BALB/c mice were intranasally inoculated once with 10(7) CFU of M. pneumoniae. Groups of mice were treated with LBM415 (50 mg/kg of body weight) or placebo subcutaneously daily for 13 days, starting 24 h after inoculation. Groups of mice were evaluated at the baseline; at days of treatment 1, 3, 6, and 13; and at 7 days after treatment. The MIC of LBM415 against M. pneumoniae was <0.005 microg/ml. LBM415-treated mice had significantly lower bronchoalveolar lavage fluid M. pneumoniae concentrations than placebo-treated mice on days 6 and 13 of treatment. Compared with placebo treatment, therapy with LBM415 significantly decreased lung histopathology scores at days 3, 6, and 13 of treatment and at 7 days after treatment. Airway obstruction was significantly lower in LBM415-treated mice than in placebo-treated mice on days 1, 3, and 6 of treatment and after 7 days of therapy, while airway hyperresponsiveness was significantly lower only on day 3 of therapy. The bronchoalveolar lavage fluid concentrations of tumor necrosis factor alpha, gamma interferon (IFN-gamma), interleukin-6 (IL-6), IL-12, KC (functional IL-8), monocyte chemotactic protein 1, macrophage inflammatory protein 1alpha, monokine induced by IFN-gamma, and IFN-inducible protein 10 were significantly reduced in LBM415-treated mice compared with the levels in placebo-treated mice. There were no differences in the bronchoalveolar lavage fluid concentrations of granulocyte-macrophage colony-stimulating factor, IL-1beta, IL-2, IL-4, IL-5, and IL-10 between the two groups of mice. LBM415 therapy had beneficial microbiologic, histologic, respiratory, and immunologic effects on acute murine M. pneumoniae pneumonia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16189089      PMCID: PMC1251520          DOI: 10.1128/AAC.49.10.4128-4136.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  45 in total

1.  In vitro and in vivo efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae.

Authors:  M Takahata; M Shimakura; R Hori; K Kizawa; Y Todo; S Minami; Y Watanabe; H Narita
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

2.  Severe acute lung injury caused by Mycoplasma pneumoniae: potential role for steroid pulses in treatment.

Authors:  M Radisic; A Torn; P Gutierrez; H A Defranchi; P Pardo
Journal:  Clin Infect Dis       Date:  2000-12       Impact factor: 9.079

3.  Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents.

Authors:  Kim Credito; Gengrong Lin; Lois M Ednie; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

4.  Antibiotic activity and characterization of BB-3497, a novel peptide deformylase inhibitor.

Authors:  J M Clements; R P Beckett; A Brown; G Catlin; M Lobell; S Palan; W Thomas; M Whittaker; S Wood; S Salama; P J Baker; H F Rodgers; V Barynin; D W Rice; M G Hunter
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

5.  Peptide deformylase as an antibacterial drug target: target validation and resistance development.

Authors:  C M Apfel; H Locher; S Evers; B Takács; C Hubschwerlen; W Pirson; M G Page; W Keck
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

6.  The T cell chemoattractant IFN-inducible protein 10 is essential in host defense against viral-induced neurologic disease.

Authors:  M T Liu; B P Chen; P Oertel; M J Buchmeier; D Armstrong; T A Hamilton; T E Lane
Journal:  J Immunol       Date:  2000-09-01       Impact factor: 5.422

Review 7.  Lymphocyte traffic control by chemokines.

Authors:  B Moser; P Loetscher
Journal:  Nat Immunol       Date:  2001-02       Impact factor: 25.606

8.  Critical role for CXCR3 chemokine biology in the pathogenesis of bronchiolitis obliterans syndrome.

Authors:  John A Belperio; Michael P Keane; Marie D Burdick; Joseph P Lynch; Ying Ying Xue; Kewang Li; David J Ross; Robert M Strieter
Journal:  J Immunol       Date:  2002-07-15       Impact factor: 5.422

9.  In vitro activities of ABT-773 and other antimicrobials against human mycoplasmas.

Authors:  Ken B Waites; Donna M Crabb; Lynn B Duffy
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

10.  Requirement of the chemokine receptor CXCR3 for acute allograft rejection.

Authors:  W W Hancock; B Lu; W Gao; V Csizmadia; K Faia; J A King; S T Smiley; M Ling; N P Gerard; C Gerard
Journal:  J Exp Med       Date:  2000-11-20       Impact factor: 14.307

View more
  10 in total

1.  Microbiologic and immunologic evaluation of a single high dose of azithromycin for treatment of experimental Mycoplasma pneumoniae pneumonia.

Authors:  Ana María Ríos; Mónica Fonseca-Aten; Asunción Mejías; Susana Chávez-Bueno; Kathy Katz; Ana María Gómez; George H McCracken; Octavio Ramilo; R Doug Hardy
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

2.  Efficacy of increasing dosages of clarithromycin for treatment of experimental Mycoplasma pneumoniae pneumonia.

Authors:  C Tagliabue; C Techasaensiri; J P Torres; K Katz; C Meek; T R Kannan; J J Coalson; S Esposito; N Principi; R Leff; J B Baseman; R D Hardy
Journal:  J Antimicrob Chemother       Date:  2011-07-25       Impact factor: 5.790

3.  In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models.

Authors:  Colin S Osborne; Georg Neckermann; Evelin Fischer; Robert Pecanka; Donghui Yu; Kari Manni; Julie Goldovitz; Kerri Amaral; JoAnn Dzink-Fox; Neil S Ryder
Journal:  Antimicrob Agents Chemother       Date:  2009-07-13       Impact factor: 5.191

4.  Respiratory tract infection with Mycoplasma pneumoniae in interleukin-12 knockout mice results in improved bacterial clearance and reduced pulmonary inflammation.

Authors:  C M Salvatore; M Fonseca-Aten; K Katz-Gaynor; A M Gomez; A Mejias; C Somers; S Chavez-Bueno; G H McCracken; R D Hardy
Journal:  Infect Immun       Date:  2006-10-30       Impact factor: 3.441

5.  Intranasal interleukin-12 therapy inhibits Mycoplasma pneumoniae clearance and sustains airway obstruction in murine pneumonia.

Authors:  C M Salvatore; M Fonseca-Aten; K Katz-Gaynor; A M Gomez; R D Hardy
Journal:  Infect Immun       Date:  2007-11-26       Impact factor: 3.441

6.  Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.

Authors:  C M Salvatore; C Techasaensiri; C Tagliabue; K Katz; N Leos; A M Gomez; G H McCracken; R D Hardy
Journal:  Antimicrob Agents Chemother       Date:  2009-01-12       Impact factor: 5.191

7.  Identification of crucial amino acids of bacterial Peptide deformylases affecting enzymatic activity in response to oxidative stress.

Authors:  Sanjay Kumar; Pavitra Kanudia; Subramanian Karthikeyan; Pradip K Chakraborti
Journal:  J Bacteriol       Date:  2013-10-18       Impact factor: 3.490

8.  The impact of steroids given with macrolide therapy on experimental Mycoplasma pneumoniae respiratory infection.

Authors:  C Tagliabue; C M Salvatore; C Techasaensiri; A Mejias; J P Torres; K Katz; A M Gomez; S Esposito; N Principi; R D Hardy
Journal:  J Infect Dis       Date:  2008-10-15       Impact factor: 5.226

9.  Drug forecast - the peptide deformylase inhibitors as antibacterial agents.

Authors:  David R P Guay
Journal:  Ther Clin Risk Manag       Date:  2007-08       Impact factor: 2.423

Review 10.  Management of Mycoplasma genitalium infections - can we hit a moving target?

Authors:  Jørgen Skov Jensen; Catriona Bradshaw
Journal:  BMC Infect Dis       Date:  2015-08-19       Impact factor: 3.090

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.